<DOC>
	<DOCNO>NCT01008813</DOCNO>
	<brief_summary>A 1-year multicenter , randomize , single-blinded , phase II trial , stratify HAART . The purpose trial evaluate immunogenicity safety A ( H1N1 ) French National Agency Research AIDS Viral Hepatitis influenza vaccine , administer without adjuvant , HIV-infected patient one two injection .</brief_summary>
	<brief_title>Clinical Trial Evaluate Immunogenicity Safety Adjuvanted A ( H1N1 ) v Influenza Vaccine Non-adjuvanted A ( H1N1 ) v Influenza Vaccine HIV-infected Patients ( ANRS 151 Hifluvac )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥ 18 year Able give write consent Covered French Social Security HIVinfected ( infection attest patient 's chart ) Patients treated HAART least 6 month , viral load inferior 50 copies/mL least 2 last visit Patients without treatment HIV least 6 month without indication start treatment follow 3 month Patients follow HIVinfection ANRS center whose home close center case influenzalike illness , consultation hospitalization center follow necessary For woman childbearing potential , use effective method contraception , willing undergo urine pregnancy test prior vaccination . Pregnancy Receipt chemotherapy , immunotherapy ( IL2 , IL7 , IV Ig ) , corticosteroid within 3 month prior enrolment Thrombopenia inferior 20 000/mm3 Febrile episode ( least 38°C rectal least 37,5°C measure orally ) within one week prior vaccination Opportunistic infection ( treat less 1 month ) Coinfection HCV treat IFNa Influenza ( clinically virologically document ) last 6 month History document autoimmune disease ( lupus , systemic inflammatory disease , ... ) Child C cirrhosis Solid organ transplant recipient Intolerance 1 component vaccine Other immunization receive within 3 week prior inclusion plan last vaccine injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>adjuvanted non-adjuvanted A ( H1N1 ) v influenza vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>